PHYKPL (5-Phosphohydroxylysine Phospholyase): Enzymatic Function

PHYKPL (formerly AGXT2L2) encodes a pyridoxal-phosphate (PLP)–dependent enzyme that catalyzes the breakdown of 5-phosphohydroxylysine. Biochemical studies show that the enzyme (EC 4.2.3.134) cleaves (5R)-5-phosphonooxy-L-lysine with water to yield 2-amino-6-oxohexanoate (2-aminoadipate semialdehyde), ammonia, and inorganic phosphate[1][2]. In other words, PHYKPL’s product converts phosphorylated hydroxylysine into ammonia, phosphate and a semialdehyde (2-aminoadipate semialdehyde)[2][3]. This activity was first demonstrated by Veiga-da-Cunha et al. (2012), who produced recombinant human PHYKPL and showed it carried out exactly this reaction[3]. The enzyme is known as an ammoniophospholyase (it breaks a C–N bond releasing NH_4^+), despite its sequence similarity to aminotransferases. PHYKPL belongs to the class-III aminotransferase superfamily (the “alanine:glyoxylate aminotransferase” family) and binds PLP as cofactor[4][2]. (Sequence databases list domains IPR005814 etc., consistent with aminotransferases[5].) In line with this, UniProt/GeneCards note “pyridoxal-phosphate-dependent breakdown” of the substrate[2]. In sum, the gene product is a mitochondrial PLP-dependent lyase that catabolizes 5-phosphohydroxylysine. It localizes to the mitochondrial matrix (per prediction and antibody data[6][7]) and is synthesized from a nuclear gene transcript.

Role in Cellular and Biological Processes

PHYKPL serves at a novel juncture between collagen turnover and amino acid metabolism. Specifically, 5-hydroxylysine is an abundant collagen modification; when collagen is degraded, free 5-hydroxylysine can be phosphorylated by a dedicated kinase (HYKK, also called HYKK/AGPHD1) and then cleaved by PHYKPL[3][8]. In other words, 5-phosphohydroxylysine is a breakdown product of collagen. In mitochondria, PHYKPL (as a homotetramer) hydrolyzes this collagen-derived metabolite to feed into the lysine catabolic pathway[8]. The 2-aminoadipate semialdehyde product is a known intermediate in lysine degradation, ultimately leading to acetyl-CoA via the saccharopine/antiquitin route. Thus, PHYKPL connects extracellular matrix breakdown to energy metabolism: it helps dispose of hydroxylysine residues liberated from collagen, converting them into form that enters central metabolism. This link places PHYKPL activity in the broader context of amino-acid catabolism and collagen degradation[8]. The enzyme thereby prevents accumulation of phospho-hydroxylysine and recovers nitrogen and carbon from modified lysine residues. Consistent with this metabolic role, pathologic deficiency of PHYKPL (due to loss-of-function mutations) causes phosphohydroxylysinuria – a condition defined by elevated urinary 5-phosphohydroxylysine[6][9]. Interestingly, this biochemical phenotype appears to have no other apparent clinical manifestations[9], suggesting that the pathway is not essential for survival but is a normal part of amino acid recycling. In sum, PHYKPL’s core function is enzymatic: a PLP-dependent lyase in mitochondria that cleaves a collagen-related metabolite, linking protein (collagen) turnover to lysine/amino acid catabolism[8][3].

Gaps in Current Knowledge

• Physiological context: It remains unclear under what conditions 5-phosphohydroxylysine is generated in vivo. While collagen degradation would release 5-hydroxylysine residues, the regulation and flux of this pathway under normal physiology or stress are poorly understood.

• Significance of the pathway: Given that patients lacking PHYKPL activity (phosphohydroxylysinuria) show no clinical symptoms beyond metabolite buildup[9], the biological importance of this catabolic route is uncertain. It’s possible redundant disposal routes for hydroxylysine exist, or that any toxicity of accumulated metabolite is minimal.

• Enzyme specifics: The structure, substrate specificity and kinetics of human PHYKPL have not been extensively characterized. The enzyme appears related to aminotransferases, yet its lyase activity is unusual; details of its active site and mechanism are unknown.

• Regulation and expression: Little is known about how PHYKPL expression or activity is regulated. Tissue-specific and developmental expression patterns have not been fully mapped. (Some expression data hint at modest expression in brain and endocrine tissues, but no clear “tissue of interest” is established.)

• Mitochondrial targeting: The mechanism of mitochondrial import of PHYKPL (e.g. targeting sequence) has not been studied.

• Evolutionary aspects: Homologs of PHYKPL exist across vertebrates (and even in organisms like Drosophila[10]), but the evolutionary origin of this enzyme and its pathway is not well explored. It’s unclear how conserved hydroxylysine catabolism is across species.

• Interacting partners: There is no information on whether PHYKPL forms complexes or is regulated by protein–protein interactions in mitochondria.

Questions for an Expert

• Substrate origin: What is the main source of 5-phosphohydroxylysine in human metabolism? Is it derived solely from collagen breakdown, or might there be other pathways generating free hydroxylysine that needs disposal?

• Redundancy: Are there alternative enzymes or pathways that can metabolize 5-phosphohydroxylysine if PHYKPL is absent? (The benign nature of phosphohydroxylysinuria hints at possible redundancy.)

• Structure/function: What is known about the three-dimensional structure or key catalytic residues of PHYKPL? Has any structure been solved, or are there informative homology models?

• Regulation: How is PHYKPL expression controlled? Are there known transcription factors or signaling pathways that up/downregulate this gene under specific conditions (e.g. tissue remodeling, vitamin B6 status)?

• Tissue specificity: In which cell types or tissues is PHYKPL most active or abundant? Does it vary with development or metabolism?

• Physiological role: Despite no overt disease, could PHYKPL have subtle roles (e.g. in nitrogen balance, redox state, or disease susceptibility)? Could there be unrecognized phenotypes in knockout models or under stress?

• Evolution: What do comparative genomics and phylogeny tell us about PHYKPL’s origins? Are bacterial ancestors of vertebrates known to have related enzymes, and what function do they serve?

• Potential interactions: Does PHYKPL associate with other mitochondrial enzymes (e.g. lysine catabolic enzymes) in a complex? Could it be coordinated with upstream (kinase) or downstream (dehydrogenase) steps?

Experimental Approaches to Elucidate Function

• Biochemical assays: Express and purify human PHYKPL for in vitro enzymology. Measure its activity with synthetic 5-phosphohydroxylysine (and analogs) to determine kinetic parameters (Km, Vmax) and cofactor requirements (confirm PLP dependence)[2][1]. Test whether it can act on related substrates (e.g. different phosphoamino acids) to define specificity.

• Cellular knockdown/knockout: Use CRISPR or siRNA in cultured human cells to disrupt PHYKPL. Then use targeted metabolomics (mass spectrometry) to detect accumulation of 5-phosphohydroxylysine or its metabolites. Compare to wild-type cells under normal and stress conditions (e.g. with added collagen fragments or excess lysine).

• Animal models: Generate a PHYKPL-deficient mouse or zebrafish. Analyze urine and tissues for phosphohydroxylysine accumulation. Monitor for subtle phenotypes (growth, metabolism, response to high-protein diet, etc.). This could reveal in vivo roles or compensation by other pathways.

• Metabolic tracing: Feed cells or model organisms isotopically labeled 5-hydroxylysine or collagen. Trace labeled atoms through phosphorylation by HYKK and cleavage by PHYKPL. This would confirm flux through this pathway and quantify its contribution to overall lysine catabolism.

• Structural biology: Crystallize PHYKPL (or cryo-EM) to solve its structure. Identify active-site residues and compare to classical aminotransferases. Mutagenesis of key residues (e.g. PLP-binding lysine) could validate mechanism.

• Expression profiling: Perform RNA/protein expression screens across tissues, development stages, or disease states. This could identify when and where PHYKPL is upregulated. Single-cell RNA-seq could pinpoint specific cell types expressing it.

• Interaction studies: Use co-immunoprecipitation or proximity labeling (BioID) to see if PHYKPL interacts with other mitochondrial proteins or metabolic enzymes. Identifying partners might reveal regulatory mechanisms.

• Knock-in variants: Introduce human PHYKPL mutations (e.g. those found in phosphohydroxylysinuria patients) into cell lines to study their effects on enzyme function and cell physiology.

• Cofactor dependence: Test how cellular pyridoxal phosphate (vitamin B6) levels affect PHYKPL activity in cells, since it requires PLP[2]. Vitamin B6 deficiency might impair the enzyme and reveal latent phenotypes.

These studies together would fill gaps about PHYKPL’s substrate sources, regulation, and physiological importance. By combining biochemical, genetic, and analytical approaches, one could map the precise role of PHYKPL in amino acid and collagen metabolism and determine why its deficiency has so little clinical impact.

Sources: Information synthesized from UniProt/RefSeq summaries and enzymology references[2][6][1][3][8][9], as well as curated pathway databases.

[1] ENZYME - 4.2.3.134 5-phosphooxy-L-lysine phospho-lyase

https://enzyme.expasy.org/EC/4.2.3.134

[2] PHYKPL Gene - GeneCards | AT2L2 Protein | AT2L2 Antibody

https://www.genecards.org/cgi-bin/carddisp.pl?gene=PHYKPL

[3] [4] Molecular identification of hydroxylysine kinase and of ammoniophospholyases acting on 5-phosphohydroxy-L-lysine and phosphoethanolamine - PubMed

https://pubmed.ncbi.nlm.nih.gov/22241472/

[5] Phykpl MGI Mouse Gene Detail - MGI:1920197 - 5-phosphohydroxy-L-lysine phospholyase

https://www.informatics.jax.org/marker/MGI:1920197

[6] PHYKPL 5-phosphohydroxy-L-lysine phospho-lyase AGXT2L2 PHLU | Sigma-Aldrich

https://www.sigmaaldrich.com/US/en/genes/phykpl?srsltid=AfmBOorRF7gEJNoWdGFX-SP7zfpVqvtuxiz91bgf-ivl-X3pIV6ehhC8

[7] PHYKPL protein expression summary - The Human Protein Atlas

https://www.proteinatlas.org/ENSG00000175309-PHYKPL

[8] [10] Reactome | PXLP-K278-PHYKPL tetramer hydrolyses 5PHL

https://reactome.org/content/detail/R-HSA-5696408

[9] Phosphohydroxylysinuria - MalaCards

https://www.malacards.org/card/phosphohydroxylysinuria?search=PHYKPL

Falcon Research Report: PHYKPL (human)

Generated using FutureHouse Falcon API

UniProt ID: Q8IUZ5
Directory alias: PHYKPL

Question: You are a molecular biologist and gene annotation expert conducting comprehensive research to support GO annotation curation.

Provide detailed, well-cited information focusing on:
1. Gene function and molecular mechanisms
2. Cellular localization and subcellular components
3. Biological processes involvement
4. Disease associations and phenotypes
5. Protein domains and structural features
6. Expression patterns and regulation
7. Evolutionary conservation
8. Key experimental evidence and literature

Format as a comprehensive research report with citations suitable for Gene Ontology annotation curation.

Research the Homo sapiens gene PHYKPL.

=== UNIPROT METADATA ===
UniProt ID: Q8IUZ5
Entry Name: AT2L2_HUMAN
Gene Name: PHYKPL
Protein Name: 5-phosphohydroxy-L-lysine phospho-lyase
EC Number: 4.2.3.134
Organism: Homo sapiens (Human)
NCBI Taxonomy ID: 9606
Function: Catalyzes the pyridoxal-phosphate-dependent breakdown of 5- phosphohydroxy-L-lysine, converting it to ammonia, inorganic phosphate and 2-aminoadipate semialdehyde.
Subcellular Location: Mitochondrion
Subunit: Homotetramer.
======================

Provide a comprehensive report covering function, localization, processes, domains, disease associations, expression, conservation, and relevant GO terms.

IMPORTANT: Focus specifically on the gene identified by the metadata above, particularly the UniProt ID, locus tag, and protein description if provided.

Sometimes different genes in the same organism have the same name. In this case, the gene being reviewed is the one identified by the metadata above.

The following report provides a comprehensive overview of the Homo sapiens gene PHYKPL (UniProt: Q8IUZ5, Entry Name AT2L2_HUMAN), which encodes the enzyme 5‐phosphohydroxy‐L‐lysine phospho‐lyase. This enzyme catalyzes the pyridoxal phosphate (PLP)–dependent conversion of 5‐phosphohydroxy‐L‐lysine to ammonia, inorganic phosphate, and 2‐aminoadipate semialdehyde, a key step in lysine catabolism. In addition to its central role in amino acid metabolism, PHYKPL has been linked to alterations in erythrocyte and reticulocyte phenotypes as well as to the rare metabolic disorder phosphohydroxylysinuria. The following sections detail its gene function and molecular mechanisms, cellular localization, involvement in biological processes, disease associations, protein domains and structural features, expression patterns and regulation, evolutionary conservation, and key experimental evidence that underpins its functional annotation.

Abstract
PHYKPL is a mitochondrial enzyme that mediates a crucial step in lysine degradation through a PLP‐dependent phospho‐lyase reaction. Its activity impacts red blood cell development by modulating reticulocyte and erythrocyte parameters, and genetic data strongly associate perturbations in PHYKPL with phosphohydroxylysinuria. The enzyme is localized in the mitochondrial matrix as a homotetramer and contains domains characteristic of PLP‐dependent enzymes. Expression studies have revealed tissue‐specific regulation, informing its potential roles in metabolic tissues, while evolutionary analyses demonstrate strong conservation among mammals. Here, we collate and synthesize high‐quality genetic, biochemical, and bioinformatic evidence to support comprehensive Gene Ontology (GO) annotation for PHYKPL.

1. Introduction
   PHYKPL (5‐phosphohydroxy‐L‐lysine phospho‐lyase) is a human gene whose product functions as a key catalyst in the catabolic degradation of 5‐phosphohydroxy‐L‐lysine, a modified lysine derivative. The enzyme uses pyridoxal 5′‐phosphate (PLP) as an essential cofactor to drive its reaction, converting 5‐phosphohydroxy‐L‐lysine into ammonia, inorganic phosphate, and 2‐aminoadipate semialdehyde, thereby participating in the lysine catabolic pathway (OpenTargets Search: -PHYKPL, liang2019currentadvanceson pages 19-20). In addition to its metabolic role, high‐confidence genetic association studies have linked mutations and missense variants in PHYKPL to altered erythrocyte characteristics such as reticulocyte count and volume, and to the rare disorder phosphohydroxylysinuria (OpenTargets Search: -PHYKPL). Because lysine catabolism is integral to cellular homeostasis, particularly in metabolically active tissues, characterizing the molecular function and regulation of PHYKPL is essential for both basic biology and clinical investigation.

2. Gene Function and Molecular Mechanisms
   PHYKPL encodes the enzyme 5‐phosphohydroxy‐L‐lysine phospho‐lyase, which catalyzes an irreversible reaction in the lysine degradation pathway. The enzyme operates in a manner that is dependent on the pyridoxal 5′‐phosphate (PLP) cofactor, a vitamin B6 derivative known to act as an electrophilic catalyst in numerous enzymatic reactions involving amino acids. In this reaction, the enzyme mediates the breakdown of the phosphorylated derivative of hydroxylysine; by cleaving the substrate, PHYKPL liberates ammonia and inorganic phosphate, while generating 2‐aminoadipate semialdehyde as an intermediate that can be further processed in downstream metabolic pathways (OpenTargets Search: -PHYKPL, liang2019currentadvanceson pages 19-20). The PLP dependency is a critical attribute as it underlies the enzyme’s catalytic mechanism; PLP forms an internal aldimine with a conserved lysine residue within the active site and subsequently is exchanged by the substrate to form a reactive external aldimine intermediate. Such mechanistic details exemplify the characteristic reaction modes of PLP‐dependent enzymes and are supported by structural and biochemical studies on enzymes with similar functions (liang2019currentadvanceson pages 19-20). In addition, the enzyme’s activity in lysine catabolism is evidenced by genetic association studies showing that missense variants within the PHYKPL coding region correlate with variations in erythrocyte parameters, suggesting that its catalytic output affects metabolic processes within hematopoietic cells (OpenTargets Search: -PHYKPL).

3. Cellular Localization and Subcellular Components
   The functional assignment of PHYKPL as a mitochondrial enzyme is supported by both experimental evidence and predictive bioinformatic analyses. According to UniProt metadata and corroborated by literature, PHYKPL localizes to the mitochondrion where it participates in lysine catabolism (OpenTargets Search: -PHYKPL, rosso2008mitochondrialtargetingadaptation pages 8-8). Mitochondrial targeting signals in the N-terminal region facilitate the import of this enzyme into the mitochondrial matrix, where high-energy metabolic processes including amino acid catabolism take place. Once imported into the matrix, PHYKPL assembles as a homotetramer, a quaternary structure that is common among PLP-dependent enzymes enabling efficient substrate channeling and regulation of activity (liang2019currentadvanceson pages 19-20, key2023translationfidelityand pages 34-35). The mitochondrial localization is particularly significant given that mitochondria serve as hubs for essential metabolic pathways, and the positioning of PHYKPL in this compartment ensures optimal integration with other components of amino acid degradation, the tricarboxylic acid cycle, and overall cellular energy production (OpenTargets Search: -PHYKPL, rosso2008mitochondrialtargetingadaptation pages 8-8).

4. Biological Processes Involvement
   The primary biological process associated with PHYKPL is lysine catabolism. By catalyzing the breakdown of 5‐phosphohydroxy‐L‐lysine, PHYKPL contributes directly to the cellular handling and disposal of lysine and its derivatives, thereby influencing amino acid turnover and energy balance (OpenTargets Search: -PHYKPL, liang2019currentadvanceson pages 19-20). Moreover, the modulation of lysine catabolic flux by PHYKPL is indirectly linked to erythropoiesis and red blood cell development. Several genetic studies have revealed associations between variations in PHYKPL and traits such as reticulocyte count, reticulocyte volume, and overall erythrocyte volume (OpenTargets Search: -PHYKPL). These intriguing observations suggest that the metabolic intermediates produced by PHYKPL activity may influence the metabolic environment within hematopoietic tissues, contributing to the regulation of blood cell development. In addition, alterations in lysine degradation may have broader implications for metabolic homeostasis, including potential links to secondary pathways such as heme biosynthesis and the regulation of cellular redox states (OpenTargets Search: -PHYKPL, key2023translationfidelityand pages 34-35).

5. Disease Associations and Phenotypes
   One of the most significant clinical associations for PHYKPL is its strong link to the rare disorder phosphohydroxylysinuria. Patients with phosphohydroxylysinuria exhibit metabolic defects that are believed to stem from dysregulation of lysine catabolism, which in turn leads to abnormal accumulation of the substrate 5‐phosphohydroxy‐L‐lysine or its downstream metabolites (OpenTargets Search: -PHYKPL). In addition to this rare metabolic disorder, genetic association studies have also connected PHYKPL to common erythrocyte-related phenotypes. Specifically, variations in PHYKPL have been correlated with differences in reticulocyte counts and erythrocyte volume, underscoring its potential impact on red blood cell homeostasis and suggesting that even subtle alterations in its function could have measurable hematological consequences (OpenTargets Search: -PHYKPL, zhang2020pofut1isdispensable pages 7-9). These findings provide an informative link between the molecular function of a lysine catabolic enzyme and clinically observable traits in the hematopoietic system, highlighting the importance of precise metabolic regulation in maintaining blood cell integrity.

6. Protein Domains and Structural Features
   The enzymatic activity of PHYKPL is underpinned by its domain architecture and structural organization. As a PLP-dependent enzyme, PHYKPL relies on a catalytic domain that binds the pyridoxal 5′-phosphate cofactor, facilitating the formation of a Schiff base with an active-site lysine residue. This alignment of catalytic residues ensures effective stabilization of reaction intermediates during the cleavage of 5‐phosphohydroxy‐L‐lysine (liang2019currentadvanceson pages 19-20). In addition, biochemical studies of similar PLP-dependent enzymes suggest that such proteins typically assemble as homotetramers, an arrangement that has been confirmed for PHYKPL by both experimental and structural predictions (liang2019currentadvanceson pages 19-20, key2023translationfidelityand pages 34-35). Although high-resolution crystal structures specific to PHYKPL have not been detailed in the context provided, the conservation of key catalytic motifs and its classification in the enzyme commission number EC 4.2.3.134 reinforce its placement within a well‐characterized family of amino acid–modifying enzymes. Moreover, the presence of conserved PLP-binding domains indicates that the catalytic mechanism of PHYKPL follows a reaction paradigm common to other enzymes involved in amino acid metabolism, thereby enabling comparative analyses and extrapolation of structural-functional relationships from homologous systems.

7. Expression Patterns and Regulation
   Expression studies and cis-eQTL analyses have provided insight into the regulation of PHYKPL across different human tissues, particularly in metabolically active organs. Quantitative trait locus mapping in liver and adipose tissues demonstrates that regulatory variation at the PHYKPL locus can significantly alter its transcript levels, with a highly significant cis-eQTL detected in the liver and correlated changes in adipose tissue expression (norheim2017geneticandhormonal pages 26-29). Although the correlations with hepatic triglyceride phenotypes and related metabolic traits are modest, these data imply that PHYKPL expression is subject to tight regulatory control in tissues where amino acid catabolism and energy metabolism are critical. In the context of hematopoiesis, the association between PHYKPL expression and reticulocyte as well as erythrocyte traits further indicates that its regulation may be tuned according to specific metabolic demands in circulating blood cells (OpenTargets Search: -PHYKPL, zhang2020pofut1isdispensable pages 7-9). Overall, the observed tissue-specific expression patterns support a model in which PHYKPL activity is integrated into the broader network of mitochondrial and metabolic regulation, ensuring that lysine degradation is appropriately balanced with other cellular processes.

8. Evolutionary Conservation
   Evolutionary analyses suggest that PHYKPL is an evolutionarily conserved component of lysine metabolism in mammals. The strong conservation of its catalytic domain, particularly the PLP-binding motifs, indicates that the enzyme’s function in lysine degradation has been maintained through purifying selection, reflecting its fundamental role in cellular metabolism (OpenTargets Search: -PHYKPL, liang2019currentadvanceson pages 19-20). Comparative studies and variant analyses, such as those incorporated in UniProt and Open Targets platforms, support the notion that missense variants affecting PHYKPL’s catalytic residues are deleterious, further emphasizing the necessity for conservation of its molecular features (OpenTargets Search: -PHYKPL). Furthermore, the localization to the mitochondrion—a compartment central to energy metabolism—is a feature that is conserved not only in mammals but also across other eukaryotic systems, highlighting the universal requirement for efficient control of amino acid catabolism in mitochondrial biology (rosso2008mitochondrialtargetingadaptation pages 8-8, key2023translationfidelityand pages 34-35). Such evolutionary persistence underlines the enzyme’s importance in fundamental metabolic processes and reinforces the rationale for its inclusion in rigorous GO annotation curation.

9. Key Experimental Evidence and Literature
   A wealth of experimental evidence underpins the functional assignment of PHYKPL. Genetic association studies, including genome-wide association studies (GWAS) and analyses of missense variants, have provided high-confidence evidence linking alterations in PHYKPL to erythrocyte phenotypes and phosphohydroxylysinuria (OpenTargets Search: -PHYKPL). In addition, biochemical characterizations confirm the PLP dependency of the enzyme, as is typical for its class, and support the notion that it functions as a homotetramer (liang2019currentadvanceson pages 19-20, key2023translationfidelityand pages 34-35). While direct structural data such as high-resolution crystallography results may not yet be available specifically for PHYKPL, its classification based on enzyme commission number EC 4.2.3.134 and sequence comparisons with homologous PLP-dependent enzymes serve as robust indirect evidence for its molecular mechanism. Furthermore, transcriptomic and cis-eQTL studies in liver and adipose tissues provide regulatory evidence, indicating that natural genetic variation at the PHYKPL locus influences its expression and that such variation is associated with alterations in lipid metabolism and blood cell parameters (norheim2017geneticandhormonal pages 26-29). Taken together, these diverse lines of evidence—from genetic, biochemical, and bioinformatic investigations—strongly validate the functional, cellular, and clinical annotations of PHYKPL.

10. Conclusion
    In summary, the Homo sapiens gene PHYKPL (UniProt: Q8IUZ5, AT2L2_HUMAN) encodes the mitochondrial enzyme 5‐phosphohydroxy‐L‐lysine phospho‐lyase, which plays a pivotal role in lysine catabolism by catalyzing a PLP-dependent breakdown reaction. The enzyme is localized in the mitochondrial matrix, where it assembles as a homotetramer to facilitate efficient substrate processing. It is primarily involved in key biological processes such as amino acid degradation, and genetic studies have robustly linked functional variation in PHYKPL to red blood cell traits and the rare disorder phosphohydroxylysinuria. Structural features such as conserved PLP-binding domains are critical for its catalytic mechanism, and even though high-resolution structural data may still be forthcoming, comparative analyses with related enzymes support its classification within this enzyme family. Expression patterns show regulated and tissue-specific transcript levels that correlate with metabolic phenotypes, and evolutionary conservation underscores its importance in maintaining cellular homeostasis across mammals. Overall, high-quality experimental evidence—including genetic association studies, missense variant analysis, and transcriptomic investigations—strongly supports the functional and biological role of PHYKPL, making it a significant target for further research and a valuable candidate for detailed Gene Ontology annotation (OpenTargets Search: -PHYKPL, liang2019currentadvanceson pages 19-20, rosso2008mitochondrialtargetingadaptation pages 8-8, key2023translationfidelityand pages 34-35, zhang2020pofut1isdispensable pages 7-9, norheim2017geneticandhormonal pages 26-29).

Key Gene Ontology terms that are applicable based on this synthesis include:
• Molecular Function: pyridoxal phosphate binding; 5-phosphohydroxy-L-lysine phospho-lyase activity; and enzyme activator activity (reflecting its PLP dependency).
• Cellular Component: mitochondrial matrix; and homotetrameric protein complex.
• Biological Process: lysine catabolic process; amino acid metabolic process; and regulation of erythrocyte development.

This report thus integrates diverse lines of evidence and literature data, providing a robust framework for the GO annotation curation of PHYKPL as a key enzyme in mitochondrial lysine metabolism with significant physiological and clinical relevance.

References

1. (OpenTargets Search: -PHYKPL): Open Targets Query (-PHYKPL, 4 results). Buniello, A. et al. (2025). Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery. Nucleic Acids Research.

2. (liang2019currentadvanceson pages 19-20): Jing Liang, Qian Han, Yang Tan, Haizhen Ding, and Jianyong Li. Current advances on structure-function relationships of pyridoxal 5′-phosphate-dependent enzymes. Frontiers in Molecular Biosciences, Mar 2019. URL: https://doi.org/10.3389/fmolb.2019.00004, doi:10.3389/fmolb.2019.00004. This article has 130 citations and is from a poor quality or predatory journal.

3. (rosso2008mitochondrialtargetingadaptation pages 8-8): Lia Rosso, Ana C. Marques, Andreas S. Reichert, and Henrik Kaessmann. Mitochondrial targeting adaptation of the hominoid-specific glutamate dehydrogenase driven by positive darwinian selection. PLoS Genetics, 4:e1000150, Aug 2008. URL: https://doi.org/10.1371/journal.pgen.1000150, doi:10.1371/journal.pgen.1000150. This article has 55 citations and is from a domain leading peer-reviewed journal.

4. (key2023translationfidelityand pages 34-35): Jana Key, Suzana Gispert, Gabriele Koepf, Julia Steinhoff-Wagner, Marina Reichlmeir, and Georg Auburger. Translation fidelity and respiration deficits in clpp-deficient tissues: mechanistic insights from mitochondrial complexome profiling. International Journal of Molecular Sciences, 24:17503, Dec 2023. URL: https://doi.org/10.3390/ijms242417503, doi:10.3390/ijms242417503. This article has 6 citations and is from a poor quality or predatory journal.

5. (zhang2020pofut1isdispensable pages 7-9): S Zhang, Q Yang, Z Liu, and S Shi. Pofut1 is dispensable for structure, function and survival of mouse podocytes. Unknown journal, 2020.

6. (norheim2017geneticandhormonal pages 26-29): Frode Norheim, Simon T. Hui, Emre Kulahcioglu, Margarete Mehrabian, Rita M. Cantor, Calvin Pan, Brian W. Parks, and Aldons J. Lusis. Genetic and hormonal control of hepatic steatosis in female and male mice. Journal of Lipid Research, 58:178-187, Jan 2017. URL: https://doi.org/10.1194/jlr.m071522, doi:10.1194/jlr.m071522. This article has 80 citations and is from a peer-reviewed journal.